FMC and Atticus have settled their dispute over chlorantraniliprole (CTPR), resulting in Atticus’s withdrawal of its declaratory judgment action against FMC. With the settlement, Atticus plans to enter the CTPR market beginning Dec. 7, 2025.
“We are pleased to arrive at this professional and respectful outcome that advances a superior chemistry through its full product life cycle and agronomic potential,” states Randy Canady, CEO, Atticus. “As the price-to-agronomic value of CTPR becomes more aligned, end-users will be empowered to use CTPR in more routine agronomic rotations for better, more cost-effective insect control.”
Historically, early commitments have led to missed opportunities once all next season’s brand alternatives were introduced. As a result, Atticus launched the Eclipse initiative to elevate product awareness prior to customers potentially staging inventory that may not prove cost competitive.
The Portfolio Branding Bars above offer a perspective on the comprehensive CTPR portfolio that Atticus deliberately pursued to sit parallel to all CTPR-branded offers while positioning Atticus as the one-stop CTPR supplier to accommodate customer preferences, according to the company.
